NewsFeeder
Headline News
PTC reports first milestone payment from Roche for spinal muscular atrophy drug
Shares of PTC Therapeutics Inc. were down 0.9% in trading on Wednesday after the company said it received its first milestone payment of $20 million from Roche Holding AG as part of their licensing and collaboration deal. PTC reported the first sales of Evrysdi, a spinal muscular atrophy treatment approved earlier this month. PTC developed the drug, and Roche is the commercial partner. PTC's stock has gained 3.5% year-to-date, while the S&P 500 is up 6.6%.
https://finance.yahoo.com/m/20ab314...32/ptc-reports-first-milestone.html?.tsrc=rss
Shares of PTC Therapeutics Inc. were down 0.9% in trading on Wednesday after the company said it received its first milestone payment of $20 million from Roche Holding AG as part of their licensing and collaboration deal. PTC reported the first sales of Evrysdi, a spinal muscular atrophy treatment approved earlier this month. PTC developed the drug, and Roche is the commercial partner. PTC's stock has gained 3.5% year-to-date, while the S&P 500 is up 6.6%.
https://finance.yahoo.com/m/20ab314...32/ptc-reports-first-milestone.html?.tsrc=rss
